IPSEN (OTCMKTS:IPSEY) Hits New 52-Week High – Should You Buy?

IPSEN (OTCMKTS:IPSEY)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $48.54 and last traded at $48.54, with a volume of 402 shares traded. The stock had previously closed at $48.21.

Wall Street Analyst Weigh In

IPSEY has been the topic of several research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, February 17th. UBS Group cut IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

IPSEN Price Performance

The stock’s fifty day moving average is $44.41 and its 200-day moving average is $38.71.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).